Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch
Executive Summary
Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.